Table 3.
Treatment after coronary microcirculatory assessment.
| Variable | Total N = 223 |
CFR ≤ 2 N = 91 |
CFR > 2 N = 117 |
p-Value | IMR ≥ 25 N = 84 |
IMR < 25 N = 121 |
p-Value |
|---|---|---|---|---|---|---|---|
| PCI | 47 (21.1) | 21 (23.1) | 26 (22.2) | 0.88 | 10 (11.9) | 36 (29.8) | 0.003 |
| PCI within: | |||||||
| LAD | 36 (16.1) | 16 (17.6) | 20 (17.1) | 0.93 | 8 (9.5) | 27 (22.3) | 0.02 |
| LMCA | 1 (0.5) | 1 (1.1) | 0 (0.0) | 0.44 | 0 (0.0) | 1 (0.8) | 0.59 |
| Cx | 9 (4.0) | 3 (3.3) | 6 (5.1) | 0.52 | 2 (2.4) | 7 (5.8) | 0.31 |
| RCA | 6 (2.7) | 4 (4.4) | 2 (1.7) | 0.25 | 0 (0.0) | 6 (5.0) | 0.04 |
| CABG | 5 (2.2) | 3 (3.3) | 2 (1.7) | 0.66 | 1 (1.2) | 4 (3.3) | 0.40 |
| Percutaneous valve intervention | 1 (0.5) | 1 (1.1) | 0 (0.0) | 0.45 | 1 (1.2) | 0 (0.0) | 0.43 |
| Surgical valve intervention | 1 (0.5) | 1 (1.1) | 0 (0.0) | 0.44 | 0 (0.0) | 1 (0.8) | 1.0 |
| Conservative treatment | 197 (88.3) | 78 (85.7) | 104 (88.9) | 0.49 | 78 (92.6) | 101 (83.5) | 0.047 |
| Conservative treatment adjustment | 39 (17.5) | 12 (13.2) | 26 (22.2) | 0.385 | 11 (13.1) | 26 (21.5) | 0.62 |
| Added pharmacotherapy | |||||||
| ACEI | 18 (8.1) | 12 (13.2) | 6 (5.1) | 0.04 | 10 (11.9) | 8 (6.6) | 0.19 |
| BB | 12 (5.4) | 5 (5.5) | 7 (6.0) | 0.88 | 6 (7.1) | 6 (5.0) | 0.51 |
| Nitrate | 12 (5.4) | 3 (3.3) | 9 (7.7) | 0.18 | 4 (4.8) | 8 (6.6) | 0.58 |
| Ranolazine | 0 (0.0) | 0 (0.0) | 0 (0.0) | - | 0 (0.0) | 0 (0.0) | - |
| Ivabradine | 1 (0.4) | 1 (1.1) | 0 (0.0) | 0.26 | 1 (1.2) | 0 (0.0) | 0.23 |
| Trimetazidine | 35 (15.7) | 19 (20.9) | 16 (13.7) | 0.17 | 19 (22.6) | 15 (12.4) | 0.053 |
| CCB DHP | 38 (17.0) | 20 (22.0) | 17 (14.5) | 0.16 | 29 (34.5) | 8 (6.6) | <0.001 |
| CCB NDHP | 4 (1.8) | 3 (3.3) | 1 (0.9) | 0.20 | 3 (3.6) | 0 (0.0) | 0.04 |
Data are presented as counts (percentages). Abbreviations: see Table 2. CABG: coronary artery bypass graft; DHP: dihydropyridine; PCI: percutaneous coronary intervention; NDHP: nondihydropyridine.